Lamivudine Articles
US ANDAs filed for generic Beyaz, Isentress and Epivir
12 January 2012
GlaxoSmithKline to refocus some research and seek efficiencies, despite posting huge 4th-qtr 2009 profits rise; applause from Science Minister
5 February 2010
Mylan confirms first-to-file patent challenge to Cephalon’s sleep-disorder drug Nuvigil
12 January 2010
FDA panel OKs Pfizer’s Selzentry for broader us in HIV naive patients, but drug criticized for its cost
12 October 2009
Strong histology data for B-MS' Baraclude
10 November 2008
GSK's Epzicom comparable to Truvada
18 August 2008
Isentress works well in untreated HIV patients
18 August 2008
Baraclude gets nod from NICE
30 June 2008
FDA starts safety review of GSK and B-MS HIV drugs
7 April 2008
Low five-year resistance for Baraclude
7 April 2008
Stock Commentary - New York week to March 3, 2008
10 March 2008
Drug firms want two-year delay in US state's RFID law
11 February 2008
UPDATE: Zimbabwe pharmacies face ARV shortages
21 January 2008
Uganda joint venture with Indian Rx firm
10 December 2007
Indonesia's ARV program attacked
12 November 2007
Less side effects with switch from Combivir to Truvada
5 November 2007
ARVs drug plant opens in Uganda
15 October 2007
Small number of combination drugs reaching the Japanese market
24 September 2007
FDA gives nod to 50th and 51st PEPFAR drugs
20 August 2007
Boeh Ing's Viramune may cut CV risk
6 August 2007
Pfizer's maraviroc fares well vs efavirenz
6 August 2007
Truvada/Sustiva cuts viral load vs Combivir/Sustiva
6 August 2007
Rwanda HIV/AIDS drug patent move
30 July 2007
Thailand and Brazil collaboration fears
28 May 2007
Japanese study group urges Zolinza appro
7 May 2007
B-MS' Baraclude "will dominate" hep B mart
23 April 2007
Promising early data for ANA380
23 April 2007
Idenix' Sebivo close to EMEA approval
5 March 2007
Strong 3-year findings for B-MS' Baraclude
6 November 2006
SMC approves Baraclude as HBV treatment for NHS in Scotland
16 October 2006
Novartis' Sebivo gains domestic approval
2 October 2006
GlaxoSmithKline in deal to supply HIV/AIDS drugs to Russia
25 September 2006
13 new drugs added to Japan's NHI list
18 September 2006
Atripla approved by FDA for use in HIV-1 therapy
17 July 2006
Baraclude receives EC approval for hep B
10 July 2006
FDA tentative appro of three-component AIDS drug
10 July 2006
GSK moves to help poorest fight HIV/AIDS
5 June 2006
B-MS' Baraclude shows efficacy in HCV trial
5 June 2006
Telbivudine performs well in hep B trial
3 April 2006
Novartis/Idenix submit telbivudine for EU appro
13 February 2006
Good efficacy for Gilead Sci's ARV combo
30 January 2006
GSK says combination HIV therapy increases treatment adherence
12 December 2005
Ranbaxy ARVs back on WHO list
22 August 2005
WHO, US FDA to share generic HIV/AIDS Rx data
22 August 2005
Good Ph III for Idenix/Novartis' telbivudine
8 August 2005
Aurobindo gets tentative appro for generic ARV
18 July 2005
Trial shows Pegasys' superior efficacy in HBV
11 July 2005
US FDA "tentative OK" for Aurobindo stavudine
11 July 2005
Ranbaxy Labs lamivudine gets US FDA approval
13 June 2005
Roche's PEGASYS gets US OK in hep B
23 May 2005
Strong results for Anadys' drug-resistant hep B drug
25 April 2005
FDA clears B-MS' Baraclude for hep B
11 April 2005
South Africa awards ARV drug tenders
14 March 2005
More US FDA HIV/AIDS drug approvals "soon"
14 March 2005
EC approves Roche's Pegasys for hepatitis B
7 March 2005
GSK rebrands HIV/ AIDS drugs for Africa
28 February 2005
Gilead reports 48-wk data from HIV study
14 February 2005
US FDA OKs first ARV triple therapy for LDCs
31 January 2005
Novartis shows off strong R&D pipeline at annual conference
31 January 2005
CHMP recommends Roche's Pegasys as hep B therapy
31 January 2005
Roche's Pegasys obtains Swiss approval for chronic hep B
10 January 2005
GSK's Kivexa granted EU approval
10 January 2005
South African TAC "may seek efavirenz license"
22 November 2004
Ranbaxy withdraws generic antiretrovirals on quality concerns
15 November 2004
Pharco gets compulsory license to make ARVs in Zambia
4 October 2004
New Essential Drugs List for South Africa
27 September 2004
Zambia set to start ARV production
27 September 2004
CHMP recommends GSK's Kivexa for HIV
27 September 2004
GSK: voluntary license for ARVs in South Africa
6 September 2004
Massive growth potential of China
6 September 2004
Three Ranbaxy ARVs taken off WHO list
16 August 2004
GSK's combi-HIV drug Epzicom OKed by FDA
9 August 2004
GSK/China deal for HIV/AIDS drugs
26 July 2004
WHO on HIV: publishes new guidelines on PMTCT, adds four drugs to pre-qualification list
26 July 2004
Cipla patents Triomune in South Africa
19 July 2004
BI and GSK to co-package HIV drugs
19 July 2004
GSK/Vertex' Lexiva effective in suppressing HIV over two years in therapy-naive patients
19 July 2004
BI and GSK to co-package HIV drugs
19 July 2004
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
